Purdue Pharma will no longer market OxyContin to U.S. doctors, says the drugmaker at the center of the opioid crisis.
Purdue will continue selling OxyContin, but will no longer send salespeople to doctors’ offices to promote it, reports the Wall Street Journal. Consequently, Purdue will cut its U.S. sale staff by more than half.
Purdue’s decision comes amid a new wave of legal action against opioid producers, which has resulted in several states suing Purdue for social and economic damages caused by the opioid epidemic.